Synthesis of acceptor substrate analogs for the study of glycosyltransferases involved in the second step of the biosynthesis of O-antigen repeating units
摘要:
O-antigens of Gram negative bacteria are polysaccharides covalently attached to lipopolysaccharides (LPS) that have roles as virulence factors. Due to the lack of defined substrates for in vitro assays only a few of the enzymes involved in the biosynthesis of O-antigens have been studied. Many O-antigens have GlcNAc at the reducing end of the oligosaccharide chain linked to pyrophosphate-lipid. We therefore designed and synthesized a series of GlcNAc-pyrophosphate-lipid analogs of the natural GlcNAc-pyrophosphate-undecaprenol acceptor substrate for studies of the acceptor specificities of O-antigen biosynthetic enzymes. We synthesized analogs with modifications of the pyrophosphate bond as well as the lipid chain. These compounds will be useful for the specificity studies of many bacterial glycosyltransferases. Knowledge of the substrate specificities is the basis for the development of specific glycosyltransferase inhibitors that could block O-antigen biosynthesis. (C) 2010 Elsevier Ltd. All rights reserved.
ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS
申请人:Oldfield Eric
公开号:US20120022024A1
公开(公告)日:2012-01-26
This disclosure relates to compositions and methods including for the inhibition, prevention, and/or treatment of microbial infections, including infections from such pathogens as
Staphylococcus aureus.
[EN] ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS<br/>[FR] COMPOSITIONS ANTI-BACTÉRIENNES ET PROCÉDÉS COMPRENANT LE CIBLAGE DE FACTEURS DE VIRULENCE DE STAPHYLOCOCCUS AUREUS
申请人:UNIV ILLINOIS
公开号:WO2010123599A9
公开(公告)日:2011-02-17
[EN] This disclosure relates to compositions and methods including for the inhibition, prevention, and/or treatment of microbial infections, including infections from such pathogens as Staphylococcus aureus. [FR] L'invention se rapporte à des compositions et à des procédés notamment pour l'inhibition, la prévention, et/ou le traitement d'infections microbiennes, y compris des infections par des agents pathogènes tels que Staphylococcus aureus.